"10.1371_journal.pone.0040331","plos one","2012-07-05T00:00:00Z","Annika Järviluoma; Tomas Strandin; Sebastian Lülf; Jérôme Bouchet; Anna R Mäkelä; Matthias Geyer; Serge Benichou; Kalle Saksela","Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland; Department of Physical Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany; Institut Cochin, CNRS (UMR8104), Université Paris Descartes, Paris, France; Inserm U1016, Paris, France; NEXT Biomed Technologies NBT Oy, Helsinki, Finland; HUSLAB, Helsinki University Central Hospital, Helsinki, Finland","Conceived and designed the experiments: AJ TS SL JB ARM MG SB KS. Performed the experiments: AJ TS SL AM. Analyzed the data: AJ TS SL ARM MG KS. Contributed reagents/materials/analysis tools: JB SB. Wrote the paper: AJ ARM MG SB KS.","The authors have the following interests. Anna R. Mäkelä is employed by NEXT Biomed Technologies NBT Oy. KS is an inventor in a patent on ligand-tailored SH3 domains owned by Next Biomed Technologies (NBT), and consulting NBT on development ultrasensitive diagnostics. JB and SB are inventors in a patent application on use of sdAb19 for inhibition of HIV-1 Nef. Patent application on the use of sdAb19 for inhibition of HIV-1 Nef (JB and SB): WO2009066241 Patent on ligand-tailored SH3 domains (KS): INPADOC family of WO0072742 There are no other patents, products in development or other marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","07","Annika Järviluoma","AJ",8,TRUE,8,4,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
